Yard signs in Florida depicting the candidates for the 2024 US presidential election (Robert Bell/INSTARimages/Cover Images via AP Images)

November 4, 2024 04:07 PM EST

FDA+

The election is Tuesday. What’s at stake for the pharma industry?

Nicole DeFeudis

Editor

The biopharma industry has been a bipartisan political target in recent years. But in the 2024 presidential election, details are scarce around key issues that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The election is Tuesday. What’s at stake for the pharma industry?

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Rare disease biopharma companies weigh in on FDA's new innovation hub

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?